The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
Location contact
L. Elliot Hong, MD
CONTACT
Yizhou Ma, PhD
CONTACT
NCT Number: NCT07743645
The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults with a family history of SSD and high versus low baseline SSD-like brain patterns
Trial opening soon.
Get Notified9 year–19 year
All sexes
Interventional
Not applicable
Houston, Texas, 77030, United States
L. Elliot Hong, MD
CONTACT
Yizhou Ma, PhD
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Over 16 weeks, participants and their parent/legal guardian(s)/caregiver(s) will attend weekly hour long family-based psychosocial intervention to work on their top 2 modifiable SSD-risk factors targeted by the risk reduction therapy (RRT)
Time frame: Baseline, 8 weeks, end of intervention (16 weeks after baseline ), 1-year follow up
This is a 21 item questionnaire and items are scored as 0 (symptom not endorsed) or 1 (symptom endorsed). Items endorsed are further assessed for level of distress (1-5) and chronicity (present 6 months, 1 year, 2 years, or more than 2 years ago). The total symptom score is calculated as the sum of distress ratings of all items at baseline with 1) "Did it bother you?" answered "Y" AND 2) endorsed as distressing at one or more previous time points. The range of the total symptom score is 0 to 105. Higher scores indicate greater distressing and persistent psychotic-like experiences.
Time frame: Baseline, end of intervention (16 weeks after baseline ), 1-year follow up
The NIH Toolbox subtests including List Sorting Working Memory, Pattern Comparison Processing Speed, and Rey Auditory Verbal Learning will be used. Higher scores indicate better cognitive performance. Raw scores of the test taker are compared to the scores in the NIH Toolbox nationally representative normative sample to derive standard scores. The mean standard score is 100 and the standard deviation (SD) is 15. A score at or near 100 indicates average ability compared with others. Scores around 115 suggest above-average ability. Scores around 130 suggest superior ability (in the top 2 percent nationally). A score around 85 suggests below-average ability. A score in the range of 70 or below suggests significant impairment.
Time frame: Baseline, end of intervention (16 weeks after baseline ), 1-year follow up
This is a 113 item questionnaire and each problem item is scored as: 0 (not true) 1(somewhat or sometimes true) and 2 (very true or often true). Raw scores are summed and converted to age- and sex-normed T-scores. Higher T-scores indicate greater overall psychopathology
Time frame: Baseline, end of intervention (16 weeks after baseline ), 1-year follow up
This is a 10 item questionnaire and each item is scored on a 5-point scale from 0(never) to 4 (very often). Positively worded items are reverse scored, and all items are summed to generate a total score ranging from 0 to 40. Higher scores indicate greater perceived stress.
Contact information is provided by the study sponsor or research team.
L. Elliot Hong, MD
CONTACT
Yizhou Ma, PhD
CONTACT
The University of Texas Health Science Center, Houston
Other
Developing Biomarker-Supported SSD Prevention
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731672
Actinomycetales Infections, Autoimmune Rheumatic Diseases
São Paulo, Brazil
View Trial DetailsNCT07714460
Prevention
La Flèche, Sarthe, France
View Trial DetailsNCT07704957
Adherence, Chlamydia Females
View Trial DetailsNCT06912685
Maltreatment, Parenting Intervention
View Trial Details